Anlotinib and Bemocizumab for Early Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old
- You have esophageal squamous cell carcinoma (confirmed by biopsy) that is stage II–IIIB, with no spread to distant organs
- You have never received chemotherapy or radiation for esophageal cancer
- Your overall health is good enough to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- Your heart, lungs, liver, kidneys, and thyroid function are basically normal
- You are willing to use birth control during and for 8 weeks after the trial, and to return for regular check-ups and blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (becotatug vedotin, tislelizumab, and chemotherapy) for esophageal squamous cell carcinoma—a type of cancer in the food tube. The study aims to see if this combination works better than standard treatments.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests the safety and effectiveness of combining two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (nab-paclitaxel) before surgery for people with a certain type of esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a combination of two drugs (anlotinib and benmelstobart) as a first treatment for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps control the cancer.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.